

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (cancelled).

Claim 2 (currently amended): A method of treating hypoglycaemia in an individual in need of such treatment, said method including the step of administering to said patient a therapeutic food composition comprising a waxy maize starch which is a heat moisture-treated starch ~~or annealing-treated starch~~, wherein the heat moisture-treated starch is prepared by treating waxy maize starch under conditions of 15-30% moisture at a temperature of 95-130°C for a period of 16-24 hours.

Claim 3 (currently amended): A method of treating an individual susceptible to hypoglycaemic episodes to prevent or decrease hypoglycaemic episode(s), said method including the step of administering to said individual a therapeutic food composition comprising a waxy maize starch which is a heat moisture-treated starch ~~or annealing-treated starch~~, wherein the heat moisture-treated starch is prepared by treating waxy maize starch under conditions of 15-30% moisture at a temperature of 95-130°C for a period of 16-24 hours.

Claims 4-9 (cancelled).

Claim 10 (previously presented): The method according to claim 3, wherein said individual has glycogen storage disease.

Claim 11 (previously presented): The method according to claim 3, wherein said individual has Type I or Type II diabetes.

Claim 12 (previously presented): The method according to claim 3, wherein said individual has liver disease.

Claim 13 (previously presented): The method according to claim 3, wherein the starch has an amylopectin content of at least 80%.

Claim 14 (cancelled).

Claim 15 (currently amended): The method according to claim 3, wherein said therapeutic food composition comprises per unit dose sufficient starch to maintain blood glucose concentration of greater than 3.0 mmol l^{-1} at 300 min post administration and wherein the starch does not cause a peak in blood glucose concentration of greater than 9.0 mmol l^{-1} .

Claim 16 (currently amended): The method according to claim 11, wherein said therapeutic food composition comprises per unit dose sufficient starch to main blood glucose concentration of greater than 2.25 mmol l^{-1} at 450 min post administration.

Claim 17 (previously presented): The method according to claim 3, wherein said therapeutic food composition comprises per unit dose greater than 50 g of starch.

Claims 18-30 (cancelled).

Claim 31 (currently amended): A therapeutic food kit, said food kit comprising:

a) a therapeutic food composition comprising a waxy maize starch which is a heat moisture-treated starch ~~or annealing-treated starch~~, wherein the heat moisture-treated starch is prepared by treating waxy maize starch under conditions of 15-30% moisture at a temperature of $95-130^{\circ}\text{C}$ for a period of 16-24 hours; and

b) instructions for treating hypoglycaemia or preventing or decreasing hypoglycaemic episode(s) by ingesting said therapeutic food composition.

Claim 32 (cancelled).

Claim 33 (currently amended): A sports nutrition foodstuff comprising a heat moisture-treated waxy maize starch, which is a hydrothermally-treated starch wherein the heat moisture-treated starch is prepared by treating waxy maize starch under conditions of 15-30% moisture at a temperature of $95-130^{\circ}\text{C}$ for a period of 16-24 hours.

Claims 34-36 (cancelled).

Claim 37 (new): The method according to claim 3, wherein the heat moisture-treated starch is prepared by treating waxy maize starch under conditions of 20% moisture at a temperature of 105°C for a period of 16 hours.

Claim 38 (new): The method according to claim 3, wherein the heat moisture-treated starch shows increased susceptibility to enzymatic degradation compared to untreated waxy maize starch.

Claim 39 (new): A method of treating hypoglycaemia in an individual in need of such treatment, said method including the step of administering to said patient a therapeutic food composition comprising a waxy maize starch which is a heat moisture-treated starch, wherein said therapeutic food composition comprises per unit dose sufficient starch to maintain blood glucose concentration of greater than 3.0 mmol l⁻¹ at 300 min post administration and wherein the starch does not cause a peak in blood glucose concentration of greater than 9.0 mmol l⁻¹.

Claim 40 (new): The method of claim 39, wherein the individual has a disorder selected from the group consisting of: glycogen storage disease; Type I diabetes; Type II diabetes; and liver disease.

Claim 41 (new): A method of treating an individual susceptible to hypoglycaemic episodes to prevent or decrease hypoglycaemic episode(s), said method including the step of administering to said individual a therapeutic food composition comprising a waxy maize starch which is a heat moisture-treated starch, wherein said therapeutic food composition comprises per unit dose sufficient starch to maintain blood glucose concentration of greater than 3.0 mmol l⁻¹ at 300 min post administration and wherein the starch does not cause a peak in blood glucose concentration of greater than 9.0 mmol l⁻¹.

Claim 42 (new): The method of claim 41, wherein the individual has a disorder selected from the group consisting of: glycogen storage disease; Type I diabetes; Type II diabetes; and liver disease.

Claim 43 (new): A therapeutic food kit, said food kit comprising:

a) a therapeutic food composition comprising a waxy maize starch which is a heat moisture-treated starch, wherein said therapeutic food composition comprises per unit dose sufficient starch to maintain blood glucose concentration of greater than 3.0 mmol l^{-1} at 300 min post administration and wherein the starch does not cause a peak in blood glucose concentration of greater than 9.0 mmol l^{-1} ; and

b) instructions for treating hypoglycaemia or preventing or decreasing hypoglycaemic episode(s) by ingesting said therapeutic food composition.